Clinical Trial
A clinical trial is a controlled research study conducted in human participants. Trials proceed in phases — Phase 1 tests safety, Phase 2 explores efficacy, and Phase 3 involves large-scale confirmation — before regulatory approval.
Overview
Clinical trials are the gold standard for evaluating whether a compound is safe and effective in humans. Phase 1 trials enroll a small number of healthy volunteers to establish safety and pharmacokinetics. Phase 2 trials enroll patients with the target condition to assess preliminary efficacy and dosing. Phase 3 trials are large randomized controlled studies comparing the compound against placebo or current standard of care. Successful completion of all phases enables a company to apply for FDA approval (or equivalent regulatory approval in other countries). The entire process typically takes 10–15 years and costs hundreds of millions to billions of dollars, which is why relatively few peptides reach clinical trial status.
Related Terms
Frequently asked questions
Do any research peptides have clinical trial data?+
Some research peptides have limited Phase 1 or Phase 2 data. However, GLP-1 agonists like Semaglutide and Tirzepatide have completed full Phase 3 programs and are FDA-approved.
What is a randomized controlled trial (RCT)?+
An RCT randomly assigns participants to receive either the study compound or a control (placebo or comparator), allowing researchers to attribute differences in outcomes to the treatment rather than chance or bias.
Why haven't more peptides advanced to clinical trials?+
Clinical trials require substantial financial investment, regulatory infrastructure, and patent protection to recoup costs. Research peptides without commercial development backing typically remain in the preclinical stage.